Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment
Cancer Treatment Reviews, 05/25/2012Dimopoulos MA et al.
This analysis demonstrated that in a high proportion of patients Len/Dex treatment can reverse multiple myeloma (MM)–related Renal impairment (RI) and restore normal function. Lenalidomide has a predominantly renal route of excretion and in patients with RI the plasma concentration and half–life of the drug are significantly increased. As a consequence, lower starting doses are required in patients with RI to avoid over–exposure and an increased risk of adverse events, while maintaining good therapeutic index.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.